Page 18 - CUA Presentation

International Prostate Cancer Guidelines

Recommendations for Molecular Testing and Treatment with PARP Inhibitors 1-8

Approval of olaparib Approval of olaparib
19 May 2020 Guidelines 21 August 2020
26 June 2020

®
Guidelines V.2.2020
21 May 2020
®
Guidelines V.1.2020
16 March 2020
Published 9 June 2020
Meeting: 4 October 2019
2021
1 Feb 2021

Guidelines
25 March 2020
Guidelines
27 June 2020

MAR OCT FEB
2020 APR MAY JUN JUL AUG SEP 2020 2021

APCCC, Advanced Prostate Cancer Consensus Conference; ASTRO, American Society for Radiation Onology; AUA, American Urological Association; CUA, Canadian Urological Association; CUOG, Canadian Uro Oncology
Group; EAU, European Association of Urology; ESMO, European Society for Medical Oncology; mCRPC, metastatic casstration-resistant prostate cancer; NCCN, National Comprehensive Cancer Network; SUO, Society of Urologic Oncology.
1. NCCN Guidelines in Clinical Oncology. Prostate Cancer. V1.2020; 2. NCCN Guidelines in Clinical Oncology. Prostate Cancer. V2.2020; 3. EAU Prostate Cancer Guidelines. https://uroweb.org/guideline/prostate-cancer/; 4. Giri VN et al. J Clin Oncol 2020;38:2798-811; 5. Parker C
et al. Ann Oncol 2020;31:1119-34; 6. Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline: https://www.auanet.org/guidelines/advanced-prostate-cancer; 7. Lynparza (olaparib) US PI; 8. Lynparza (olaparib) Product Monograph; 8. Saad F et al. CUAJ 2021;15:E81-90.